Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly—A Subgroup Analysis of Routine Clinical Practice Data

Table 6

Proportion of patients who had attained one or several treatment targets at the end of the 3-month tapentadol PR treatment.

	Patients aged >65 years	Patients aged ≤65 years
(a) Attainment of at least 50% reduction in pain intensity vs. baseline	67.6% (n = 725)	74.1% (n = 274)
(b) Attainment of intended pain intensity	65.1% (n = 725)	65% (n = 274)
(c) Attainment of additional individual treatment target	87.8% (n = 713)	91.5% (n = 272)
(d) Attainment of (b) and/or (c) (combined response rate)	87.9% (n = 728)	92% (n = 274)

n, number of patients with valid data; PR, prolonged release.